VANCOUVER, British Columbia / Dec 20, 2023 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024, at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).
A live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.
About AbCellera Biologics Inc.
AbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
| Last Trade: | US$4.03 |
| Daily Change: | 0.18 4.68 |
| Daily Volume: | 2,199,529 |
| Market Cap: | US$1.180B |
May 01, 2024 April 08, 2024 March 11, 2024 | |
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
